NAGE — Niagen Bioscience, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1386570 ·
Last close
$1.87
Market Cap
$148.10M
52W High
$7.12
52W Low
$1.84
ADV30
547,906
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 27,192,000 | 17,105,000 | -1,587,000 | -1,173,000 | 108,694,000 | 69,509,000 | 25,620,000 |
| Jun 2026 | 29,785,000 | 19,314,000 | 700,000 | 963,000 | 106,589,000 | 66,740,000 | 24,061,000 |
| Mar 2026 | 31,474,000 | 19,976,000 | 1,576,000 | 6,318,000 | 114,329,000 | 66,397,000 | 31,999,000 |
| Dec 2025 | 33,839,000 | 21,704,000 | 2,103,000 | 4,132,000 | 106,406,000 | 64,636,000 | 29,873,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,882,000
Investing CF
$5,000,000
Financing CF
$-4,663,000
CapEx
$-303,000
Dividends Paid
—
Buybacks
$-5,121,000
EPS Diluted TTM
$0.12
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-158,420,000
Inventory
$20,524,000
Receivables
$6,840,000
ST Investments
—
EBIT TTM
$2,792,000
Pretax Income TTM
$11,055,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$122,290,000
EBITDA
$3,863,000
Free Cash Flow
$2,920,000
Enterprise Value
$97,003,280
Total Cash
$69,357,000
Total Debt
$2,077,000
Shares Out
79,196,903
Trailing EPS
$0.12
Book Value
$1.05
ROE
13.3%
ROA
1.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 129,423,000 | 14,296,000 | 17,382,000 | 106,406,000 | 29,873,000 | 76,533,000 | 13,504,000 |
| Dec 2024 | 99,597,000 | 7,726,000 | 8,550,000 | 68,278,000 | 22,184,000 | 46,094,000 | 12,109,000 |
| Dec 2023 | 83,570,000 | -5,599,000 | -4,938,000 | 54,964,000 | 26,508,000 | 28,456,000 | 7,117,000 |
| Dec 2022 | 72,050,000 | -18,628,000 | -16,540,000 | 54,057,000 | 25,385,000 | 28,672,000 | -15,098,000 |
TTM Snapshot
Revenues TTM
$129,084,000
NetIncome TTM
$15,991,000
OpCashFlow TTM
—
Assets (Latest)
$106,589,000
Forward EPS
$-0.06
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.87 · call volume: 3 · put volume: 60
Expected Move to 2026-12-18:
±$1.00
(53.48%) —
implied range
$0.87 –
$2.87
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRLBF | Cresco Labs Inc. | $146.15M | $0.41 | — |
| BAK | BRASKEM SA | $145.81M | $0.85 | — |
| LTBR | LIGHTBRIDGE Corp | $138.00M | $3.56 | — |
| FF | FutureFuel Corp. | $131.59M | $3.00 | — |
| ARQ | Arq, Inc. | $129.03M | $2.92 | — |
News headlines (Yahoo Finance, 1h cache)
Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging
2026-11-16 13:32 · Yahoo
Niagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ Plus
2026-11-12 13:32 · Yahoo
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
2026-11-09 13:32 · Yahoo
Niagen (NAGE) Q3 2026 Earnings Call Transcript
2026-11-05 15:20 · Yahoo
Niagen Bioscience Inc Q3 2026 Earnings Call Summary
2026-11-05 13:30 · Yahoo
Niagen Bioscience Inc (NAGE) Q3 2026 Earnings Call Highlights: Cash Flow Positive Despite Sales ...
2026-11-05 11:11 · Yahoo
Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates
2026-11-04 23:45 · Yahoo
Niagen Bioscience: Q3 Earnings Snapshot
2026-11-04 21:55 · Yahoo
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
2026-11-04 21:02 · Yahoo
Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline
2026-10-28 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.